logo
FibroGen_Building
NovaQuest is a strategic financial partner that is aligned with the company's growth ambitions and demonstrates confidence in the anticipated commercial opportunity and launch performance of EVRENZO™.

FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management

FibroGen, Inc. (NASDAQ: FGEN) today announced a royalty monetization financing with NovaQuest Capital Management (NovaQuest) that will result in proceeds to FibroGen in the amount of $50 million, bringing non-dilutive capital to drive innovation and growth

By FibroGen, Inc.
Published - Nov 07, 2022, 04:07 PM ET
Last Updated - Mar 21, 2024, 11:05 AM EDT
  • Strengthens balance sheet with strategic non-dilutive capital to support strategic priorities
  • Supported by global launches of EVRENZO™ in the territories partnered with Astellas Pharma Inc.
  • FibroGen will receive $50 million in total cash upfront
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024